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Abstract
The changes occurring in the field of rheumatoid arthritis (RA) over
the past decade or two have encompassed new therapies and, in
particular, a new look at the clinical characteristics of the disease
in the context of therapeutic improvements. It has been shown that
composite disease activity indices have special merits in following
patients, that disease activity governs the evolution of joint
damage, and that disability can be dissected into several
components – among them disease activity and joint damage. It
has also been revealed that aiming at any disease activity state
other than remission (or, at worst, low disease activity) is
associated with significant progression of joint destruction, that
early recognition and appropriate therapy of RA are important
facets of the overall strategy of optimal clinical control of the
disease, and that tight control employing composite scores
supports the optimization of the therapeutic approaches. Finally,
with the advent of novel therapies, remission has become a reality
and the treatment algorithms encompassing all of the above-
mentioned aspects will allow us to achieve the rigorous aspirations
of today and tomorrow.
Rheumatologists and people with arthritis whose memories
span the last two decades have witnessed developments in
the clinical understanding of rheumatoid arthritis (RA) which
most would have regarded as science fiction had someone
predicted them. These (r)evolutionary changes relate (a) to
the possibility of influencing all major characteristics asso-
ciated with the disease: signs and symptoms, joint damage,
disability, quality of life, and other important outcomes like
joint replacement and working capacity, comorbidity, and
economic consequences, (b) to the reporting of clinical trial
results, (c) to the recognition of time as an important element
not only in the progression of RA but also in our treatment
strategies when it comes both to early therapeutic
interference and to swift switching of therapies, and (d) to the
profoundness of the response to novel therapies and
therapeutic strategies. Because these advances have
entailed profound changes in paradigms, they can be seen as
virtually iconoclastic. Therefore, in this review, we will devote
a separate section to each of these four developments.
A. Influencing major characteristics of the
disease
A new look at assessing active disease
Clinical fact 1
Composite indices are the best depicters of
disease activity. The degree of disease activity
at the start of a disease-modifying therapy is a
major determinant of the disease activity
attainable in treatment.
Background and evidence
The pivotal clinical manifestation of RA is a polyarticular
synovitis, which is a consequence of the underlying cellular
and molecular inflammatory events leading to pain, swelling
due to synovial thickening and effusion, and stiffness of the
joints. While initially individual signs and symptoms, such as
swollen joint counts or morning stiffness, or laboratory
variables, such as erythrocyte sedimentation rate or C-reactive
protein (CRP), have been thought to sufficiently reflect activity
and were used to follow patients in clinical practice, it was the
parallel activities of clinical researchers in Europe and the US
and of committees of the American College of Rheumatology,
the European League Against Rheumatism, and the
International League against Rheumatism which led to the
recognition that only a limited number of variables were
reliable and sensitive to change and that composite indices
using such a limited spectrum of disease characteristics
would capture disease activity best in terms of reliability,
validity, applicability across patients, and sensitivity to change
[1-9]. Indeed, the individual components of these ‘core sets’
reflect different aspects of RA. For example, swollen joint
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counts and acute-phase reactants are best associated with
joint damage [10-12], even though the correlation between
swollen joint counts and acute-phase response is relatively
weak. In contrast, functional impairment is best associated
with tender joint counts [10,12]. These few examples show
that composite indices encapsulate variables that relate to
the spectrum of RA and that they also comprise information
provided by the evaluator, the patient, or both and often an
‘objective’ laboratory variable as well [13]. Consequently,
changes in these scores, response criteria using these instru-
ments, or disease activity states employing these indices to
categorize the extent of disease expression have provided
important information about the relation of the range of
disease activity with intermediate and long-term outcomes
and have been pivotal in our evaluation of therapeutic
success in clinical trials [5,7,8,13]. Importantly, however, it
appears that the degree of disease activity at any point in
time, such as at the beginning of a new treatment course, is
an important predictor, on the group level, of disease activity
in the longer term, even with effective therapy [14].
Disease activity is the driver of joint damage
Clinical fact 2
Joint damage is a consequence of the
inflammatory process (disease activity over
time). Joint space narrowing and erosions by
radiography depict related but distinct
components of joint damage that may develop
separately.
Background and evidence
The hallmark of RA that distinguishes it most from all other
arthritides is the damage elicited in the joints. The RA synovial
membrane directly invades bone, entailing osteoclast
activation to carry out this job [15,16]. Likewise, the products
activated in the course of the inflammatory response, whether
originating from synovial cells or chondrocytes, lead to
degradation of the cartilage matrix [17,18]. All of these events
are a consequence of the activation of many cell populations
and, ultimately, of the upregulation of proinflammatory cyto-
kines [19,20]. By whichever means they themselves become
activated, they induce a plethora of inflammatory products,
including degradative enzymes, which mediate most if not all
of the total phenotypic expression of RA, including joint
destruction. The fact that CRP is induced by the proinflam-
matory cytokine interleukin-6 (IL-6) and the observation that
CRP levels over time correlate with joint damage [10,21]
indirectly link joint damage to the inflammatory cytokine levels.
However, as indicated before, the correlation of CRP with
joint destruction is lower than that of swollen joint counts but
higher than that of tender joint counts.
It has been unequivocally shown that the relationship of time
averaged disease activity, and its change in response to
therapy, as assessed by various composite indices, corre-
lates well with the extent of radiographic joint damage or the
degree of inhibition of its progression, respectively [1,8,21,22].
These correlations pertain to both cartilage damage, as
reflected radiologically by joint space narrowing, and bone
destruction, as depicted by erosions, which can be captured
reliably and validly using respective scores [23]. Recent data
suggest that these two processes may be related but distinct
and can be separated by detailed analyses and even by
specific therapies [24,25].
Disability is a multifarious feature
Clinical fact 3
Disability comprises an activity-related
component that is fully reversible and a
destruction-related component that is
irreversible. Clinical trial design needs to
account for this complexity. Interference with
disease activity will reverse the activity-related
segment and prevent the accrual of the
damage-related part.
Background and evidence
Failure of functioning is the most critical endpoint for an
organ or an individual. In RA, physical functioning is the major
outcome of interest given the impact of its impairment on the
person, the family, and society. Various instruments have
been developed to capture disability and its consequences
on quality of life, and the most frequently used ones in RA are
the health assessment questionnaire (HAQ) disability index
and the short form-36 (SF-36), including its physical compo-
nent subscale [26,27]. However, disability is a complex
feature: it comprises disease-specific as well as non-disease-
specific elements. Among the latter, psychological well-being
(which may or may not be related to RA), comorbidities
(which may or may not be related to RA or its treatment), and
age constitute important determinants [28]. However, the
disease-specific portion has at least two components since
pain and stiffness impair physical function even in the
absence of joint damage (such as in very early active
disease), while patients with severely destroyed joints may
suffer from disability even in the absence of any disease
activity. Indeed, several studies have directly or indirectly
provided evidence of this bicomponential nature of the HAQ
index [29-31]. Importantly, however, with increasing joint
destruction, there is an increase in irreversible disability, even
in states of stringent clinical remission [31]. Thus, in these
patients, the floor that can be reached rests at a higher level.
Therefore, irreversible disability can be averted only by
prevention of joint destruction, which (as discussed above) is
a consequence of disease activity. Since joint damage is also
related to the duration of the disease, similar associations of
reversibility and irreversibility can be found for disease
duration [31] and similar findings can be made using a morePage 3 of 9
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generic quality-of-life instrument such as the SF-36. Impor-
tantly, however, these observations have a bearing on the
response to therapy: in clinical trials of patients with long-
standing disease, the functional improvement may be limited
to an extent that does not allow one to discern active
effective medication from placebo [32]; this indicates the
importance of careful clinical trial design that accounts for the
potential irreversible disability. Importantly, instruments
enabling clinicians and trialists to predict the degree of
reversibility of functional impairment would be desirable.
Inter-relationship of disease activity and disability with
various secondary outcomes characteristic of rheumatoid
arthritis, such as comorbidity, mortality, and costs
Clinical fact 4
The reduction in life expectancy as well as
comorbidities associated with rheumatoid
arthritis (RA), such as cardiovascular disease
and lymphoma, and economic consequences,
including loss of working capacity, are
associated primarily with the severity of RA as
manifested by chronic high disease activity
and long-term irreversible disability.
Background and evidence
Mortality is increased in patients with RA. This reduction in
life expectancy has been shown unequivocally to be related
to the chronic active disease process and the associated
disability [33-37]. However, mortality is due primarily to
comorbidities, and among those conditions cardiovascular
events are particularly relevant [38,39]. Importantly, cardio-
vascular disease is highly related to the inflammatory
response [40,41]. Likewise, the prevalence of lymphoma is
increased in RA and has been shown to be associated with
the degree of inflammation and thus, again, chronic active
disabling disease [38,42].
RA also leads to multiple economic consequences. While
addressing health economics in a broader sense is beyond
the scope of this article, it needs to be mentioned that direct
medical costs comprise not only costs for drugs but also
those for other medical attention (including joint surgery) and
that, with increasing HAQ scores, joint replacement surgery
and use of other health care resources increase dramatically
[43-45]. Among the many indirect costs, work disability
constitutes an important economic consequence of RA.
Within 10 years, up to 60% of RA patients may be fully or
partly work-incapacitated [46-48]. Again, this is directly
related to HAQ scores [46,48,49]. Thus, active disabling
disease is generally associated with higher direct and indirect
costs in RA [45,50,51]. Therefore, disease activity, as a
sequel to the inflammatory events, directly or indirectly steers
all of the characteristics and consequences of RA (Figure 1),
which in turn have partial influence on each other as further
detailed in this commentary.
B. The importance of appropriate disease
activity reporting
It’s the state, not just the change
Clinical fact 5
Therapy for rheumatoid arthritis needs to aim
at least to achieve low disease activity by
composite scores and, ideally, remission.
Clinical trial reporting has to account for both
improvement and disease activity categories,
and the latter also needs to be evaluated
during follow-up in clinical practice.
Background and evidence
Disease activity is rarely a dichotomous quality (active versus
inactive) but, like temperature, constitutes a continuum.
Composite disease activity indices, but also visual analogue
scales or joint counts, are like a thermometer, reflecting this
by providing a continuous measure. Nevertheless, to under-
stand the impact of disease activity on the vast arrays of
outcomes in RA, to select patients for clinical trials, to
interpret laboratory findings or results from basic scientific
Available online http://arthritis-research.com/content/11/1/204
Figure 1
Inter-relationship of disease activity and outcomes in rheumatoid
arthritis: a spinning wheel.investigations, to judge the indication or the necessity to
change therapy, and to define the most appropriate thera-
peutic aims, categorical criteria are helpful. Therefore, cate-
gories or states of high, moderate, and low disease activity as
well as remission have been identified for the most commonly
used indices: the disease activity score (DAS), disease
activity score using 28 joint counts (DAS28), Simplified
Disease Activity Index (SDAI), and Clinical Disease Activity
Index (CDAI) [13]. Indeed, the lower the disease activity
category that can be attained under therapy, the lower the
progression of joint damage [12,22].
On the other hand, in clinical practice and clinical trials,
response to or improvement of therapy has been the center
of attention [5,52]. Improvement or response, however,
relates primarily to absolute or relative changes of disease
activity, and actual activity at the endpoint will depend on the
baseline values. Thus, response criteria do not account, or at
least do not sufficiently account, for the disease activity state
to be aimed for. This is further supported by observations
that a symptom state acceptable to patients requires greater
amounts of improvement as baseline disease activity
increases. This reveals that the achievement of a particular
state is the major desirable goal for patients [53]. Indeed,
patients with an approximately 50% or higher improvement
of their disease activity will suffer from continuing profound
joint destruction if their disease activity is not brought into at
least the low disease activity category [54]. Furthermore,
even in states of low disease activity, there is a smoldering
progression of joint damage with therapies like methotrexate
(MTX), and therefore only remission leads to the arrest of
joint damage [22].
On the basis of the above, achieving remission ought to be the
ultimate goal when treating RA. The definition of remission,
however, is still under debate and many rheumatologists
would like to see remission defined as a state of no residual
disease activity [12]. Nevertheless, some of the composite
scores allow for significant residual disease activity and
currently the most stringent remission criteria appear to be
those defined by the SDAI and CDAI. Indeed, only when
remission by these criteria is fulfilled will patients stop
destroying their joints and reduce their functional impairment
maximally and thus possibly to normality [54], regardless of
their level of improvement.
These and other insights mandate a change in clinical trial
reporting by requesting the provision of information on cate-
gories of disease activity attained in the course of a trial and
at the endpoint rather than just providing levels of improve-
ment [55]. Indeed, the first randomized double-blind controlled
trial using a state as the primary endpoint has recently been
published [56]. Thus, assessing disease activity has under-
gone major changes and has become both standardized and
the standard of care. Such assessment is also important in
clinical practice.
C. Time and timing as well as appropriate
follow-up are important facets of
rheumatoid arthritis and the care for
rheumatoid arthritis
Early recognition and therapy are mandates
Clinical fact 6
Early recognition of rheumatoid arthritis is
important for early institution of disease-
modifying anti-rheumatic drug therapy, which
is more efficacious than delayed treatment.
Background and evidence
The destructive process of RA starts within the first few
weeks or months of disease, and by 2 years the majority of
patients have damaged joints [57,58]. Indeed, there is
evidence from experimental arthritis that osteoclast activation
may occur even before the onset of clinical symptoms [59].
Several trials have revealed that early institution of disease-
modifying anti-rheumatic drug (DMARD) therapy, when
compared with late start, improves the outcome of RA [60-
62]. The major gain is twofold: it appears that the more
established disease may be somewhat less responsive to the
same drugs when compared with early disease [62] (‘window
of opportunity’). The second asset is the earlier prevention of
accrual of damage and thus an overall reduction in joint
destruction and risk of irreversible disability. However, early
therapy requires early diagnosis. Alas, current criteria for the
classification of RA are based on patients with long-standing
RA and criteria for early RA are needed and awaited [63].
Regular tight follow-up and change of therapy are
important
Clinical fact 7
Tight follow-up examinations (every 3 months)
and appropriate switch of therapy after a
maximum of 3 to 6 months in patients who do
not achieve low disease activity or remission
are important constituents of modern
therapeutic approaches to rheumatoid arthritis.
Background and evidence
Another aspect of time relates to the observation that chronic
active disease, despite therapy, will lead to increasing joint
damage (see above). Therefore, treatment that does not
reduce disease activity to a low state should be switched
rapidly. Since in clinical trials maximal therapeutic responsive-
ness can be seen within 3 to 6 months and since disease
activity at 3 to 6 months is an excellent predictor of activity at
12 months [14], all necessary decisions can be made at that
time, for the sake of the patient and consequently for society.
However, this requires tightly timed control examinations and
definitions of thresholds for switching insufficiently effective
Arthritis Research & Therapy    Vol 11 No 1 Smolen and Aletaha
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better outcomes [64-66].
D. New therapies and therapeutic strategies
have revolutionized clinical developments
Tumor necrosis factor inhibitors plus methotrexate lead
to profound clinical responses and uncouple the close
relationship between disease activity and joint damage
Clinical fact 8
Remission has become a highly achievable
goal with the advent of biological therapies.
Moreover, tumor necrosis factor inhibitors plus
methotrexate significantly retard joint damage,
even in patients who do not respond well
clinically, thus reducing the propensity to
accumulate irreversible disability with active
disease.
Background and evidence
As indicated before, achieving low disease activity and
remission need to be the ultimate therapeutic goals in RA in
order to affect all of its attributes, which comprise destruction
of bone and cartilage and accumulation of irreversible
disability. The introduction of tumor necrosis factor (TNF)
inhibitors, particularly in combination with MTX, has
revolutionized the scene in this regard: never before have
response rates been so profound, with ACR70% (a 70%
improvement in symptoms according to the American
College of Rheumatology criteria) improvement criteria
fulfilled in up to about 40% of patients [67]. While
proportions of patients with ‘DAS28 remission’ often exceed
ACR70% response rates, stringent remission according to
the SDAI criteria has been observed at the end of a 1-year
trial of a TNF inhibitor plus MTX in more than 20% of patients,
whereas less than 15% of patients remained in the high
disease activity category; in contrast, almost 30% of patients
treated with MTX monotherapy still resided at high disease
activity levels and approximately 12% had attained remission
at 1 year [22]. In clinical practice, this success can be
surpassed: in our clinic, about 25% of patients are in SDAI
remission and only about 5% are in high disease activity [68];
this is in line with findings that most patients in today’s clinical
practice do not fulfill entry criteria for clinical trials [69]. A
scenario in which 1 in 4 patients has reached remission and
only 1 in 20 resides in high disease activity is a dream that
probably no rheumatologist would have dared to entertain just
few years ago – a novel reality challenging us to aim for more.
One of the most surprising findings in the decade since the
introduction of TNF inhibitors was the observation that TNF
inhibitors in combination with MTX would arrest or at least
significantly retard progression of joint damage even in
patients with highly active RA despite anti-TNF plus MTX
treatment and even in those who had no clinical benefit at all
[70]. This indicated that TNF blockade plus MTX uncoupled
the tight linkage between clinical disease activity and joint
damage, and these findings were confirmed in other studies
[71]. Although the underlying mechanisms responsible for
these findings have not been worked out, they may have to
do with threshold levels of bioactive TNF [72]. Importantly, in
contrast to MTX monotherapy, the combination with MTX
arrested progression of joint damage in patients who
achieved low disease activity rather than remission and
retarded it significantly even in those who had moderate or
high disease activity [22]. Nevertheless, also with TNF
inhibitor plus MTX therapy, progression of joint destruction
increased with increasing disease activity, albeit at a lower
level and slope [22].
Extinction of extra-articular manifestations and
amyloidosis
Clinical fact 9
Effective therapy, in particular with
methotrexate (MTX) and more pronounced
with biologicals plus MTX, has abolished the
bulk of extra-articular manifestations and
amyloidosis, has reduced disease-related
comorbidity such as cardiovascular disease
and lymphoma, and has essentially normalized
life expectancy.
Background and evidence
Extra-articular manifestations and complications have been
major causes of death in RA. These abnormalities concerned
mainly the occurrence of vasculitis, secondary amyloidosis,
malignancy, infections, and cardiac events. All of them have
been related to the severity of the disease [73-75]. Already
with its appropriate use (that is, by rapid escalation and
employing high enough doses [76,77]), MTX was found to
interfere with disease activity and thus to reduce the levels of
rheumatoid factor and acute-phase reactants. In particular,
vasculitis and amyloidosis became rare due to the better
control of disease activity. Moreover, the incidences of lym-
phoma and cardiovascular disease have declined signifi-
cantly, leading to increased survival rates [42,78]. The
improvement in all of these outcomes appears to have been
uniformly expanded by the advent of TNF inhibitors, which
allowed clinicians to further reduce the clinical and
serological disease activity [79,80], resulting in further
improved survival - at least in observational studies [81,82].
The novel therapies allow for a modification of
treatment strategies and have significant economic
consequences
Clinical fact 10
Novel algorithms that encompass regular
disease activity assessment, change or
modification of therapy upon insufficient
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low disease activity or even remission, and the
use of glucocorticoids and biological agents
may allow for rapid achievement of optimal
therapeutic responses in the vast majority of
patients. This will not only improve quality of life
but also lead to a reduction in the need for joint
surgery and to the preservation of working ability.
Background and evidence
With the availability of biological agents that today comprise
not only TNF and IL-1 inhibitors but also a B-cell-depleting
agent, a co-stimulation inhibitor, and (currently in Japan and
likely in the near future in other parts of the world) an IL-6
receptor antibody, the armamentarium to treat RA has
dramatically expanded [67]. The concomitant insights that
patients in clinical practice also should be followed using
composite indices and ought to be tightly controlled, the
significant effect of switching therapy if predefined low
disease activity criteria are not reached [64,66], and the
finding that long-term efficacy can be predicted within the
short term after starting treatment [14] have allowed for the
introduction of treatment algorithms that might further
improve outcome in RA [83]. Additional information from
clinical trials has also revealed that the combination of
synthetic DMARDs with glucocorticoids has significant
efficacy that may come close to that of the combination of
DMARDs with biological agents [66,84-87]. In contrast, the
usefulness of combining synthetic DMARDs without the
addition of glucocorticoids is still unresolved [66,88].
The profound efficacy of novel treatment strategies,
including biological agents, on disease activity, joint
destruction, physical function, and quality of life also has
profound consequences on economic aspects. On the one
hand, these agents are costly and may not be affordable
under many circumstances. On the other hand, effective
therapy ought to lead to a reduction in other direct and
indirect costs that are afforded otherwise. This cost
reduction is, indeed, seen. For example, in parallel to the
advent of novel therapies, the necessity to perform joint
replacement surgery has decreased: while in the last decade
approximately 530 total hip joint replacements per year were
performed in Sweden in patients with inflammatory arthritis,
this number steadily declined in the present decade to
approximately 300 in 2006, contrasting their increase in
osteoarthritis [89]. Likewise, employment rates and
employability increase in the course of effective therapy [49],
suggesting the resurrection or maintenance of the working
capacity of patients, reduction of early retirement rates, and
improvement or preservation of quality of life.
Taken as a whole, our clinical understanding of RA has
expanded significantly over the past decade. These
developments have already dramatically changed or will be
realized in the near future in clinical trial design and clinical
practice, allowing further improvements in the approach to
successful therapy of RA.
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